Ophthalmology

NCX 470 0.1% eye drops reduced IOP more than latanoprost in individuals with open-angle glaucoma or ocular hypertension in the phase 3 Mont Blanc trial.

Retina expert shares his strategy for managing a patient recently diagnosed with nAMD who started on bevacizumab, discussing criteria for transitioning to more efficacious therapy.

Ehsan Rahimy, MD addresses barriers like step edits with bevacizumab and biosimilars in nAMD, emphasizing the impact of insurance-guided choices on treatment outcomes and advocating for a personalized approach.

Metformin demonstrated a protective effect against new-onset geographic atrophy, which persisted and was more pronounced in individuals without diabetes.

A cohort analysis in the UK observed no significant association between sildenafil use and AMD prevention in men with erectile dysfunction.

A post-hoc analysis of the Ocular Hypertension Treatment Study shows the inclusion of a PRS improved the prediction of POAG onset in patients with ocular hypertension.

Oral minocycline was not associated with a decrease in GA enlargement over 24 months, compared with the run-in phase, in a recent phase 2 nonrandomized trial.

Nesvategrast was safe and well tolerated but did not exhibit a statistically significant impact on the severity or progression of diabetic retinopathy in the phase 2 DR:EAM trial.

Study links childhood amblyopia with increased risk of cardiometabolic dysfunction in adulthood.

A water-free cyclosporine ophthalmic solution (SHR8028) more effectively improved total corneal fluorescein staining versus vehicle, but showed no superiority in dryness score, in phase 3 findings.

Published one-year results from PULSAR and PHOTON show extended dosing regimens with aflibercept 8 mg were non-inferior to aflibercept 2 mg for treating wet AMD and DME.

Continuous glucose monitoring was associated with lower odds of diabetic retinopathy development, even after adjusting for hemoglobin A1c levels.

People of increasing age and worse socioeconomic status were more likely to be unwilling-in-principle to participate in home-monitoring vision tests.

Clobetasol propionate ophthalmic suspension 0.05% for post-ocular surgery pain marks the first new steroid in the ophthalmic market in over 15 years.

A secondary analysis of cross-sectional data found that serum albumin levels negatively correlated with the prevalence of diabetic retinopathy.

Our February 2024 ophthalmology month-in-review features an in-depth look into global vision loss rates, a new clinical quiz on AAO guidelines, and two episodes of our flagship ophthalmology podcast, New Insight with Veeral Sheth, MD.

The newest version of ChatGPT accurately responded to most multiple-choice questions on ophthalmic cases but performed better on non-image–based questions.

Brassica Pharma Pvt. Ltd. is voluntarily recalling eye ointment products with expiration dates from February 2024 to September 2025.

A large language model demonstrated comparative diagnostic accuracy and completeness in glaucoma and retina disease to fellowship-trained ophthalmologists.

Worse examination-based and self-reported vision impairment was associated with depressive and anxiety symptoms among adults aged ≥65 years.

A recent case series analysis found the fungal keratitis prevalence may be twice as high in rural compared with non-rural areas in the United States.

Test your knowledge with this clinician quiz! In this quiz, we test your knowledge on clinical assessment recommendations for patients with inherited retinal diseases based on 2022 guidelines from the American Academy of Ophthalmology.

In a new episode of New Insight with Veeral Sheth, MD, a trio of retina specialists host a well-rounded conversation on recent conference news, the anniversary of a landmark agent, and what’s to come in 2024 for the specialty.

Since the Baby Boomers are transitioning into older age by 2040 and 2050, the dramatic rise in the global aging population will increase demands for ophthalmic care.

Long-term anti-VEGF treatment for nAMD was linked to a reduction in mortality risk, with a slight increase in CVD risk, across 16-years of follow-up in Denmark.

Data from the phase 2 METforMIN trial do not support the use of oral metformin for reducing the progression of geographic atrophy.

Vision screening rates for amblyopia showed substantial increase after photoscreening expansion, but patients who were Asian, Black, and Hispanic were less likely to be screened.

As diabetic retinopathy severity progresses, both vision-related and health-related scales show a significant deterioration in quality of life scores.

Faricimab showed sustained vision improvements and retinal drying up to 72 weeks for both branch and central RVO in the phase 3 BALATON and COMINO studies.

This new warning for consumers cautions against use of Rebright, South Moon, or FivFivGo eye drops as a result of potential eye infection risks.